Harrow

HROW

Market cap $1.45B

A real-world PMS study based on a large population demonstrates comparable safety profile of SB11 (BYOOVIZ ® / AMELIVU ® ) to reference ranibizumab In treatment-naïve patients, SB11 provided functional and anatomical improvements, while BCVA and CST were well maintained in patients who were switched from other anti-VEGF treatments to SB11, adding clinical confidence in using SB11 INCHEON, Korea and NASHVILLE, Tenn., July 20, 2026 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd.

NASHVILLE, Tenn., July 20, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the presentation of three studies supporting IHEEZO® (chloroprocaine HCl ophthalmic gel 3%), a broadly labeled low viscosity ocular anesthetic gel, and BYOOVIZ® (ranibizumab-nuna)i, an FDA-approved biosimilar referencing LUCENTISii (ranibizumab) at the American Society of Retina Specialists (ASRS) 2026 Annual Meeting. Collectively, the presentations expand the growing body of clinical and real-world evidence supporting Harrow's retina portfolio and reinforce Harrow's commitment to generating quality evidence that strengthens physician confidence, improves patient experience, and supports long-term product adoption and innovation.

Expands Harrow's Growing Retina Portfolio with an Interchangeable Ranibizumab Biosimilar Expands Harrow's Growing Retina Portfolio with an Interchangeable Ranibizumab Biosimilar

INCHEON, Korea--(BUSINESS WIRE)-- #Byooviz--Samsung Bioepis Co., Ltd. today announced the relaunch of BYOOVIZ® (ranibizumab-nuna) in the United States (US), in partnership with Harrow (Nasdaq: HROW). Harrow became responsible for commercialization of BYOOVIZ® (ranibizumab-nuna), a biosimilar referencing LUCENTIS1 (ranibizumab), and OPUVIZ™ (aflibercept-yszy), a biosimilar referencing EYLEA2 (aflibercept), upon full transition of commercialization rights from Biogen back to Samsung Bioepis by the end of 20.

Harrow shares gain after relaunching Verkazia in the United States, aiming to improve access to an FDA-approved VKC treatment for pediatric patients.

Harrow Inc. (NASDAQ:HROW) on Wednesday announced the relaunch of VERKAZIA (cyclosporine ophthalmic emulsion) 0.1%, a prescription treatment for vernal keratoconjunctivitis (VKC), a serious allergic eye condition that primarily affects children.

NASHVILLE, Tenn., June 10, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the re-launch of VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1%, a prescription therapy indicated for the treatment of vernal keratoconjunctivitis (VKC), a serious allergic eye disease that primarily affects children.

NASHVILLE, Tenn., May 27, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will present at William Blair's 46th Annual Growth Stock Conference on Wednesday, June 3, 2026, at 8:40 AM CT, in Chicago, IL.

MONSEY, N.Y., May 13, 2026 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating whether Harrow, Inc. (Nasdaq: HROW) (“HROW”) has violated the federal securities laws after the company advised that VEVYE revenue of $20.9 million during the first quarter of 2026 was below expectations due to an estimated $8 million gross-to-net reduction associated with new commercial coverage for VEVYE.

Harrow, Inc. (HROW) Q1 2026 Earnings Call Transcript